Completed OBSERVATIONAL NCT04370652

Medical Treatment of Peyronie's Disease With Collagenase Clostridium Histolyticum

Medical Treatment of Peyronie's Disease With Collagenase Clostridium Histolyticum (CCH or Xiapex®): Sexual and Psychological Impact and Results From 156 Patients' Questionnaires Data

Sponsor: University Hospital, Montpellier

Conditions Peyronie Disease

Updated 4 times since 2020 Last updated: Apr 28, 2020 Started: Jan 1, 2015 Primary completion: Dec 1, 2019 Completion: Dec 30, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Peyronie Disease and is currently completed. University Hospital, Montpellier leads this study, which shows 4 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2020 — Jan 2021 [monthly]

Completed

First recorded

Jan 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University Hospital, Montpellier

Data source: University Hospital, Montpellier

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Montpellier, France